Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Dark GG, et al. Among authors: barrett e. J Clin Oncol. 2005 Mar 20;23(9):1859-66. doi: 10.1200/JCO.2005.02.028. Epub 2005 Feb 7. J Clin Oncol. 2005. PMID: 15699482 Clinical Trial.
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Giles FJ, et al. Among authors: barrett e. Cancer. 2004 Apr 1;100(7):1449-58. doi: 10.1002/cncr.20132. Cancer. 2004. PMID: 15042679 Free article. Clinical Trial.
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E. Gordon AN, et al. Among authors: barrett e. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92. doi: 10.1111/j.1525-1438.2005.00137.x. Int J Gynecol Cancer. 2005. PMID: 16174225 Free article. Clinical Trial.
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK. Moulder SL, et al. Among authors: barrett e. Clin Cancer Res. 2017 Jul 15;23(14):3529-3536. doi: 10.1158/1078-0432.CCR-16-1496. Epub 2017 Jan 4. Clin Cancer Res. 2017. PMID: 28053022 Clinical Trial.
Maternal affective symptoms and sleep quality have sex-specific associations with placental topography.
Shah RG, Salafia CM, Girardi T, Rukat C, Brunner J, Barrett ES, O'Connor TG, Misra DP, Miller RK; program collaborators for Environmental influences on Child Health Outcomes. Shah RG, et al. Among authors: barrett es. J Affect Disord. 2024 May 26:S0165-0327(24)00844-9. doi: 10.1016/j.jad.2024.05.108. Online ahead of print. J Affect Disord. 2024. PMID: 38806063
BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing weight control and exercise programmes for women with breast cancer related lymphoedema: a feasibility trial.
Harvie M, Livingstone K, McMulllan D, Pegington M, Lombardelli C, Adams J, Farragher M, Barrett E, Bundred N. Harvie M, et al. Among authors: barrett e. Breast Cancer Res Treat. 2024 May 17. doi: 10.1007/s10549-024-07356-0. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38758461
1,201 results